Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
Jul. 08 | Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours | MT |
Jul. 08 | SANOFI : Jefferies maintains a Buy rating | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 123B | - | ||
+57.48% | 823B | C+ | ||
-7.18% | 353B | C+ | ||
+15.37% | 320B | B- | ||
+7.45% | 295B | C+ | ||
+13.62% | 239B | B+ | ||
+14.55% | 220B | B- | ||
-0.33% | 219B | A+ | ||
+8.14% | 167B | C+ | ||
-2.99% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- 0O59 Stock
- Ratings Sanofi